CY1111046T1 - Πολυμορφα τετομιλαστης - Google Patents
Πολυμορφα τετομιλαστηςInfo
- Publication number
- CY1111046T1 CY1111046T1 CY20101100965T CY101100965T CY1111046T1 CY 1111046 T1 CY1111046 T1 CY 1111046T1 CY 20101100965 T CY20101100965 T CY 20101100965T CY 101100965 T CY101100965 T CY 101100965T CY 1111046 T1 CY1111046 T1 CY 1111046T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ray powder
- powder diffraction
- diffraction spectrum
- crystal
- tetomilast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει κρύσταλλο τετομιλάστης που παράγεται ευκόλως βιομηχανικά σε μεγάλο όγκο. (1) κρύσταλλο ένυδρου τετομιλάστης που έχει φάσμα περίθλασης σκόνης ακτινών Χ που ουσιαστικά είναι ίδιο όπως το φάσμα περίθλασης σκόνης ακτίνων Χ που δείχνεται στο Σχήμα, (2) κρύσταλλο ανύδρου τετομιλάστης τύπου Α που έχει φάσμα περίθλασης σκόνης ακτίνων Χ που ουσιαστικά είναι το ίδιο όπως το φάσμα περίθλασης σκόνης ακτίνων Χ που δείχνεται στο Σχήμα 4, (3) κρύσταλλο ανύδρου τετομιλάστης τύπου C που έχει φάσμα περίθλασης σκόνης ακτίνων Χ που ουσιαστικά είναι το ίδιο όπως το φάσμα περίθλασης σκόνης ακτίνων Χ που δείχνεται στο Σχήμα 8, (4) κρύσταλλο διαλυτώματος ακετονιτριλίου τετομιλάστης που έχει φάσμα περίθλασης σκόνης ακτίνων Χ που ουσιαστικά είναι το ίδιο όπως φάσμα περίθλασης σκόνης ακτίνων Χ που δείχνεται στο Σχήμα 10 και (5) μείγμα που συνίσταται από τον ανωτέρω κρύσταλλο ανύδρου τετομιλάστης τύπου Α και κρύσταλλο ανύδρου τετομιλάστης τύπου Β. Αυτοί οι κρύσταλλοι είναι σταθεροί στην θερμότητα και την υγρασία και επίσης είναι εξαιρετικοί όσον αφορά την ιδιότητα αποσάθρωσης και την ιδιότητα διαλυτοποίησης δισκίων. Συνεπώς, αυτοί οι κρύσταλλοι κατά προτίμηση χρησιμοποιούνται ως φαρμακευτικές συνθέσεις.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006075307 | 2006-03-17 | ||
EP07739373A EP1999128B1 (en) | 2006-03-17 | 2007-03-15 | Tetomilast polymorphs |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111046T1 true CY1111046T1 (el) | 2015-06-11 |
Family
ID=38069222
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100965T CY1111046T1 (el) | 2006-03-17 | 2010-10-25 | Πολυμορφα τετομιλαστης |
CY20121100994T CY1113262T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφα τετομιλαστης |
CY20121100996T CY1113263T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφο τετομιλαστης |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100994T CY1113262T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφα τετομιλαστης |
CY20121100996T CY1113263T1 (el) | 2006-03-17 | 2012-10-23 | Πολυμορφο τετομιλαστης |
Country Status (27)
Country | Link |
---|---|
US (4) | US8501949B2 (el) |
EP (4) | EP2311833A1 (el) |
JP (2) | JP4182363B2 (el) |
KR (6) | KR101168630B1 (el) |
CN (4) | CN101365697B (el) |
AR (1) | AR059911A1 (el) |
AT (1) | ATE476433T1 (el) |
AU (1) | AU2007239906B2 (el) |
BR (1) | BRPI0706224A2 (el) |
CA (4) | CA2725810C (el) |
CY (3) | CY1111046T1 (el) |
DE (1) | DE602007008212D1 (el) |
DK (3) | DK1999128T3 (el) |
ES (3) | ES2348630T3 (el) |
HK (3) | HK1124062A1 (el) |
IL (4) | IL192237A (el) |
MY (2) | MY143808A (el) |
NO (1) | NO20083000L (el) |
PH (1) | PH12015502374A1 (el) |
PL (3) | PL1999128T3 (el) |
PT (3) | PT1999128E (el) |
RU (2) | RU2408597C2 (el) |
SG (4) | SG10201408225VA (el) |
SI (3) | SI2311832T1 (el) |
TW (1) | TWI394753B (el) |
WO (1) | WO2007119496A1 (el) |
ZA (2) | ZA200805235B (el) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117069780A (zh) | 2016-10-06 | 2023-11-17 | 协和发酵生化株式会社 | 胞苷二磷酸胆碱的晶体及其制造方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2078447T3 (es) * | 1990-06-15 | 1995-12-16 | Merck & Co Inc | Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales. |
DE69132944T2 (de) * | 1990-11-30 | 2002-11-21 | Otsuka Pharmaceutical Co., Ltd. | Azolederivate als Inhibitor von Superoxide-Radikalen |
JP4300373B2 (ja) | 1996-09-30 | 2009-07-22 | 大塚製薬株式会社 | サイトカイン産生抑制剤及び接着抑制剤 |
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
US6221153B1 (en) * | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
GB9922963D0 (en) * | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
JP4336913B2 (ja) | 1999-02-12 | 2009-09-30 | 大塚製薬株式会社 | アミド誘導体の製造方法 |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
JP3713577B2 (ja) | 2001-07-24 | 2005-11-09 | 大塚製薬株式会社 | 慢性閉塞性肺疾患治療薬 |
ATE305299T1 (de) * | 2001-07-24 | 2005-10-15 | Otsuka Pharma Co Ltd | Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
WO2005058835A2 (en) * | 2003-12-16 | 2005-06-30 | Teva Pharmaceutical Industries Ltd. | Methods of preparing aripiprazole crystalline forms |
-
2007
- 2007-03-14 TW TW096108801A patent/TWI394753B/zh not_active IP Right Cessation
- 2007-03-15 CA CA2725810A patent/CA2725810C/en not_active Expired - Fee Related
- 2007-03-15 EP EP11152503A patent/EP2311833A1/en not_active Withdrawn
- 2007-03-15 MY MYPI20082153A patent/MY143808A/en unknown
- 2007-03-15 WO PCT/JP2007/055931 patent/WO2007119496A1/en active Application Filing
- 2007-03-15 KR KR1020117016944A patent/KR101168630B1/ko not_active IP Right Cessation
- 2007-03-15 DK DK07739373.4T patent/DK1999128T3/da active
- 2007-03-15 CA CA2634100A patent/CA2634100C/en not_active Expired - Fee Related
- 2007-03-15 PL PL07739373T patent/PL1999128T3/pl unknown
- 2007-03-15 EP EP10160007A patent/EP2206711B1/en not_active Not-in-force
- 2007-03-15 RU RU2008127324/04A patent/RU2408597C2/ru not_active IP Right Cessation
- 2007-03-15 PL PL11152502T patent/PL2311832T3/pl unknown
- 2007-03-15 SG SG10201408225VA patent/SG10201408225VA/en unknown
- 2007-03-15 KR KR1020117028259A patent/KR101252994B1/ko not_active IP Right Cessation
- 2007-03-15 CA CA2725698A patent/CA2725698C/en not_active Expired - Fee Related
- 2007-03-15 RU RU2009147223/04A patent/RU2441002C2/ru not_active IP Right Cessation
- 2007-03-15 SG SG2011043296A patent/SG172706A1/en unknown
- 2007-03-15 AU AU2007239906A patent/AU2007239906B2/en not_active Ceased
- 2007-03-15 SG SG2011043304A patent/SG172707A1/en unknown
- 2007-03-15 SI SI200731066T patent/SI2311832T1/sl unknown
- 2007-03-15 SI SI200731065T patent/SI2206711T1/sl unknown
- 2007-03-15 AT AT07739373T patent/ATE476433T1/de active
- 2007-03-15 PL PL10160007T patent/PL2206711T3/pl unknown
- 2007-03-15 US US12/086,587 patent/US8501949B2/en not_active Expired - Fee Related
- 2007-03-15 KR KR20127033350A patent/KR101482374B1/ko not_active IP Right Cessation
- 2007-03-15 KR KR1020087016527A patent/KR101083611B1/ko not_active IP Right Cessation
- 2007-03-15 CN CN2007800020022A patent/CN101365697B/zh not_active Expired - Fee Related
- 2007-03-15 EP EP11152502A patent/EP2311832B1/en not_active Not-in-force
- 2007-03-15 SI SI200730386T patent/SI1999128T1/sl unknown
- 2007-03-15 PT PT07739373T patent/PT1999128E/pt unknown
- 2007-03-15 SG SG2011043312A patent/SG172708A1/en unknown
- 2007-03-15 MY MYPI20114235 patent/MY151343A/en unknown
- 2007-03-15 CN CN2011100656708A patent/CN102174046B/zh not_active Expired - Fee Related
- 2007-03-15 ES ES07739373T patent/ES2348630T3/es active Active
- 2007-03-15 ES ES11152502T patent/ES2390957T3/es active Active
- 2007-03-15 DE DE602007008212T patent/DE602007008212D1/de active Active
- 2007-03-15 PT PT11152502T patent/PT2311832E/pt unknown
- 2007-03-15 EP EP07739373A patent/EP1999128B1/en not_active Not-in-force
- 2007-03-15 CA CA2725649A patent/CA2725649C/en not_active Expired - Fee Related
- 2007-03-15 PT PT10160007T patent/PT2206711E/pt unknown
- 2007-03-15 ZA ZA200805235A patent/ZA200805235B/xx unknown
- 2007-03-15 DK DK11152502.8T patent/DK2311832T3/da active
- 2007-03-15 KR KR1020107025457A patent/KR101118943B1/ko not_active IP Right Cessation
- 2007-03-15 DK DK10160007.0T patent/DK2206711T3/da active
- 2007-03-15 BR BRPI0706224-9A patent/BRPI0706224A2/pt not_active IP Right Cessation
- 2007-03-15 CN CN2011100656661A patent/CN102174045A/zh active Pending
- 2007-03-15 ES ES10160007T patent/ES2390926T3/es active Active
- 2007-03-15 KR KR1020117028260A patent/KR20110136902A/ko not_active Application Discontinuation
- 2007-03-15 CN CN201110065650.0A patent/CN102174044B/zh not_active Expired - Fee Related
- 2007-03-16 AR ARP070101070A patent/AR059911A1/es unknown
- 2007-03-19 JP JP2007069799A patent/JP4182363B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-16 IL IL192237A patent/IL192237A/en unknown
- 2008-07-03 JP JP2008174664A patent/JP5197196B2/ja not_active Expired - Fee Related
- 2008-07-07 NO NO20083000A patent/NO20083000L/no not_active Application Discontinuation
-
2009
- 2009-04-30 HK HK09104006.5A patent/HK1124062A1/xx not_active IP Right Cessation
- 2009-04-30 HK HK11112850.1A patent/HK1159079A1/xx not_active IP Right Cessation
- 2009-04-30 HK HK11112851.0A patent/HK1159080A1/xx not_active IP Right Cessation
-
2010
- 2010-03-09 ZA ZA2010/01687A patent/ZA201001687B/en unknown
- 2010-10-25 CY CY20101100965T patent/CY1111046T1/el unknown
-
2011
- 2011-07-21 IL IL214252A patent/IL214252A0/en unknown
- 2011-07-21 IL IL214254A patent/IL214254A0/en unknown
- 2011-07-21 IL IL214253A patent/IL214253A/en not_active IP Right Cessation
-
2012
- 2012-10-23 CY CY20121100994T patent/CY1113262T1/el unknown
- 2012-10-23 CY CY20121100996T patent/CY1113263T1/el unknown
-
2013
- 2013-03-04 US US13/784,652 patent/US8993601B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,260 patent/US9145404B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/830,625 patent/US20150352095A1/en not_active Abandoned
- 2015-10-13 PH PH12015502374A patent/PH12015502374A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118637T1 (el) | Νεα κρυσταλλικη μορφη iii της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν | |
CY1118805T1 (el) | Νεες μορφες 5-αζακιτιδινης | |
CY1124222T1 (el) | Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ | |
CY1110929T1 (el) | Παραγωγα πυριδαζινονης ως αγωνιστες υποδοχεων θυρεοειδικης ορμονης | |
CY1106881T1 (el) | (3-οξο-3,4-διυδρο-κινοξαλιν-2-υλο-αμινο) - βενζαμιδικα παραγωγα και σχετικες ενωσεις ως αναστολεις της φωσφορυλασης γλυκογονου για την αντιμετωπιση του διαβητη και της παχυσαρκιας. | |
CY1117820T1 (el) | Δικυκλικες ετερο-κυκλικες ενωσεις σαν καταστολεις κινασης (kinase) πρωτεϊνης | |
CY1115750T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει ενα ετεροκυκλικο διαμορφωτη μεταφορεων κασετας συνδεσης με ατρ | |
CY1114284T1 (el) | Σουλφονυλοπυρρολες ως hdac αναστολεις | |
CY1108378T1 (el) | 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu | |
CY1111143T1 (el) | Καινοφανη παραγωγα κυανοπυριδινης χρησιμα στην αντιμετωπιση καρκινου και αλλων διαταραχων | |
CY1111702T1 (el) | Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1 | |
SE0102299D0 (sv) | Compounds | |
SE0102300D0 (sv) | Compounds | |
TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
CY1112916T1 (el) | 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση | |
CY1113944T1 (el) | Παραγωγα ν-(πυραζολ-3-υλ)-βενζαμιδης ως ενεργοποιητες γλυκοκινασης | |
CY1110392T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
CY1113257T1 (el) | Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων | |
UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
CY1109568T1 (el) | Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων | |
AR064692A1 (es) | Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos | |
CR7939A (es) | Nueva modificacion cristalina del anhidrato de boscalida | |
RS50629B (sr) | Amidni prolek gemcitabina, kompozicije i njihova primena | |
EA200870018A1 (ru) | Новый комплекс применения для стабилизации гербицидных композиций и способы его синтеза и использования | |
DOP2010000089A (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas |